Annual report pursuant to Section 13 and 15(d)

Segments

v3.6.0.2
Segments
12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Segments
Segments
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of Bio-Reference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the years ended December 31,
(In thousands)
2016
 
2015
 
2014
Revenue from services:
 
 
 
 
 
Pharmaceutical
$

 
$

 
$

Diagnostics
1,012,129

 
329,599

 
8,426

Corporate

 
140

 
240

 
$
1,012,129

 
$
329,739

 
$
8,666

Revenue from products:
 
 
 
 
 
Pharmaceutical
$
83,467

 
$
80,146

 
$
76,983

Diagnostics

 

 

Corporate

 

 

 
$
83,467

 
$
80,146

 
$
76,983

Revenue from transfer of intellectual property:
 
 
 
 
 
Pharmaceutical
$
126,065

 
$
81,853

 
$
5,285

Diagnostics

 

 
191

Corporate

 

 

 
$
126,065

 
$
81,853

 
$
5,476

Operating (loss) income:
 
 
 
 
 
Pharmaceutical
$
(9,841
)
 
$
(40,395
)
 
$
(94,401
)
Diagnostics
(3,393
)
 
(10,294
)
 
(21,647
)
Corporate
(60,041
)
 
(46,512
)
 
(27,725
)
Less: Operating loss attributable to noncontrolling interests

 
(1,280
)
 
(2,042
)
 
$
(73,275
)
 
$
(98,481
)
 
$
(145,815
)
Depreciation and amortization:
 
 
 
 
 
Pharmaceutical
$
18,254

 
$
10,245

 
$
7,936

Diagnostics
78,233

 
31,918

 
6,894

Corporate
89

 
85

 
97

 
$
96,576

 
$
42,248

 
$
14,927

Loss from investment in investees:
 
 
 
 
 
Pharmaceutical
$
(7,665
)
 
$
(7,105
)
 
$
(3,587
)
Diagnostics
13

 

 

Corporate

 

 

 
$
(7,652
)
 
$
(7,105
)
 
$
(3,587
)
Revenues:
 
 
 
 
 
United States
$
1,014,389

 
$
344,464

 
$
14,142

Ireland
137,785

 
78,989

 

Chile
35,364

 
29,885

 
29,154

Spain
15,812

 
16,622

 
21,323

Israel
15,317

 
18,107

 
20,638

Mexico
2,988

 
3,671

 
5,807

Other
6



 
61

 
$
1,221,661

 
$
491,738

 
$
91,125


(In thousands)
December 31,
2016
 
December 31,
2015
Assets:
 
 
 
Pharmaceutical
$
1,294,916

 
$
1,258,011

Diagnostics
1,408,522

 
1,479,841

Corporate
63,181

 
61,336

 
$
2,766,619

 
$
2,799,188

Goodwill:
 
 
 
Pharmaceutical
$
251,817

 
$
251,225

Diagnostics
452,786

 
492,123

Corporate

 

 
$
704,603

 
$
743,348


During the year ended December 31, 2016, no customer represented more than 10% of our total consolidated revenue. During the year ended December 31, 2015, revenue recognized under the Pfizer Transaction represented 13% of our total consolidated revenue. During the year ended December 31, 2014, one customer of our pharmaceutical segment represented 13% of our total consolidated revenue. As of both December 31, 2016 and December 31, 2015, one customer represented more than 10% of our accounts receivable balance.
The following table reconciles our Property, plant and equipment, net between U.S. and foreign jurisdictions: 
(In thousands)
December 31, 2016
 
December 31, 2015
PP&E:
 
 
 
U.S.
$
100,716

 
$
113,307

Foreign
22,115

 
18,491

Total
$
122,831

 
$
131,798